Disparities in survival by insurance status in follicular lymphoma.
暂无分享,去创建一个
[1] B. Sommers. Why Health Insurance Matters-and Why Research Evidence Should Too. , 2017, Academic medicine : journal of the Association of American Medical Colleges.
[2] Atul A. Gawande,et al. Health Insurance Coverage and Health — What the Recent Evidence Tells Us , 2017, The New England journal of medicine.
[3] G. Salles,et al. Idelalisib is effective in patients with high-risk follicular lymphoma and early relapse after initial chemoimmunotherapy. , 2017, Blood.
[4] B. Esmaeli,et al. Prognostic Value of the Staging System for Eyelid Tumors in the 7th Edition of the American Joint Committee on Cancer Staging Manual. , 2017, Ophthalmic plastic and reconstructive surgery.
[5] J. Cerhan,et al. 2016 US lymphoid malignancy statistics by World Health Organization subtypes , 2016, CA: a cancer journal for clinicians.
[6] A. Haynes,et al. Impact of Health Insurance Expansion on the Treatment of Colorectal Cancer. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] J. Cerhan,et al. Outcomes following watchful waiting for stage II–IV follicular lymphoma patients in the modern era , 2016, British journal of haematology.
[8] A. Jemal,et al. Association Between the Affordable Care Act Dependent Coverage Expansion and Cervical Cancer Stage and Treatment in Young Women. , 2015, JAMA.
[9] L. Harrison,et al. Disparities in survival by insurance status in patients with Hodgkin lymphoma , 2015, Cancer.
[10] L. Sehn,et al. Randomized Phase II Trial Comparing Obinutuzumab (GA101) With Rituximab in Patients With Relapsed CD20+ Indolent B-Cell Non-Hodgkin Lymphoma: Final Analysis of the GAUSS Study. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] J. Cerhan,et al. Early Relapse of Follicular Lymphoma After Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Defines Patients at High Risk for Death: An Analysis From the National LymphoCare Study. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] Jeffery A. Jones,et al. A phase 1/1b study of rituximab, bendamustine, and ibrutinib in patients with untreated and relapsed/refractory non-Hodgkin lymphoma. , 2015, Blood.
[13] J. Cerhan,et al. Event-Free Survival at 12 Months (EFS12) from Diagnosis Is a Robust Endpoint for Disease-Related Survival in Patients with Follicular Lymphoma in the Immunochemotherapy Era , 2014 .
[14] A. Jemal,et al. Insurance status is related to diffuse large B‐cell lymphoma survival , 2014, Cancer.
[15] G. Salles,et al. PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma. , 2014, The New England journal of medicine.
[16] Ash A. Alizadeh,et al. An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage , 2013, Nature Medicine.
[17] Summer S. Han,et al. Improvements in observed and relative survival in follicular grade 1-2 lymphoma during 4 decades: the Stanford University experience. , 2013, Blood.
[18] S. Montoto,et al. Watchful waiting in low-tumor burden follicular lymphoma in the rituximab era: results of an F2-study database. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] A. Epstein,et al. Mortality and access to care among adults after state Medicaid expansions. , 2012, The New England journal of medicine.
[20] Amy Y. Chen,et al. Disparities in the Early Adoption of Chemoimmunotherapy for Diffuse Large B-cell Lymphoma in the United States , 2012, Cancer Epidemiology, Biomarkers & Prevention.
[21] Andrew Lister,et al. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial , 2011, The Lancet.
[22] Adele Seniori Costantini,et al. InterLymph hierarchical classification of lymphoid neoplasms for epidemiologic research based on the WHO classification (2008): update and future directions. , 2010, Blood.
[23] E. Ward,et al. The Association of Insurance and Stage at Diagnosis Among Patients Aged 55 to 74 Years in the National Cancer Database , 2010, Cancer journal.
[24] Giovanni Martinelli,et al. Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] L. Elting,et al. Factors Associated With Immunotherapy Use Among Newly Diagnosed Cancer Patients , 2009, Medical care.
[26] C. Clarke,et al. Improvements in survival after follicular lymphoma by race/ethnicity and socioeconomic status: a population-based study. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[27] J. Rossi,et al. Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 study. , 2008, Blood.
[28] R. Marcus,et al. Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[29] Amy Y. Chen,et al. Association of insurance status and ethnicity with cancer stage at diagnosis for 12 cancer sites: a retrospective analysis. , 2008, The Lancet. Oncology.
[30] A. Bleyer,et al. Delays in cancer diagnosis in underinsured young adults and older adolescents. , 2007, The oncologist.
[31] J. Gribben. How I treat indolent lymphoma. , 2007, Blood.
[32] T. Ittel,et al. Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology Study. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[33] N. Schmitz,et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of t , 2005, Blood.
[34] C. Lynch,et al. Improved survival of follicular lymphoma patients in the United States. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[35] P. Solal-Céligny. Follicular Lymphoma International Prognostic Index. , 2004, Current treatment options in oncology.
[36] Indiana Strombom,et al. Socioeconomic Risk Factors for Breast Cancer: Distinguishing Individual- and Community-Level Effects , 2004, Epidemiology.
[37] C. Bradley,et al. Late Stage Cancers in a Medicaid-insured Population , 2003, Medical care.
[38] S. Robert. Community-level socioeconomic status effects on adult health. , 1998, Journal of health and social behavior.
[39] B. Nathwani,et al. A clinical evaluation of the International Lymphoma Study Group Classification of non-Hodgkin's lymphoma: a report of the Non-Hodgkin's Lymphoma Classification Project , 1997 .
[40] H. Tilly,et al. Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d'Etude des Lymphomes Folliculaires. Groupe d'Etude des Lymphomes de l'Adulte. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[41] R. Deyo,et al. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. , 1992, Journal of clinical epidemiology.
[42] S. Long,et al. Access To Care And Affordability Have Improved Following Affordable Care Act Implementation; Problems Remain. , 2016, Health affairs.
[43] Andrew Ma,et al. Comparison of Cases Captured in the National Cancer Data Base with Those in Population-based Central Cancer Registries , 2013, Annals of Surgical Oncology.
[44] Michael Halpern,et al. Association of Insurance with Cancer Care Utilization and Outcomes , 2008, CA: a cancer journal for clinicians.
[45] T. Lister,et al. Patterns of survival in patients with recurrent follicular lymphoma: a 20-year study from a single center. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.